Virginia 2025 Regular Session

Virginia House Bill HB1724 Compare Versions

Version 1 (Old)

Version 2 (New)

Old	New		Differences
1	1		2025 SESSION
2	2
3		-	~~ENROLLED~~
	3	+	SENATE SUBSTITUTE
4	4
5		-	~~VIRGINIA ACTS OF ASSEMBLY -- CHAPTER~~
	5	+	25107574D
6	6
7		-	An Act to amend and reenact 54.1-3442.02 of the Code of Virginia and to amend the Code of Virginia by adding in Title 32.1 a chapter numbered 7.3, consisting of sections numbered 32.1-276.12 through 32.1-276.19, relating to Prescription Drug Affordability Board established; drug cost affordability review.
	7	+	HOUSE BILL NO. 1724
8	8
9		-	~~[H 1724]~~
	9	+	AMENDMENT IN THE NATURE OF A SUBSTITUTE
10	10
11		-	Approved
	11	+	(Proposed by the Senate Committee on Finance and Appropriations
	12	+
	13	+	on February 14, 2025)
	14	+
	15	+	(Patron Prior to SubstituteDelegate Delaney)
	16	+
	17	+	A BILL to amend and reenact 54.1-3442.02 of the Code of Virginia and to amend the Code of Virginia by adding in Title 32.1 a chapter numbered 7.3, consisting of sections numbered 32.1-276.12 through 32.1-276.19, relating to Prescription Drug Affordability Board established; drug cost affordability review.
	18	+
	19	+
12	20
13	21		Be it enacted by the General Assembly of Virginia:
14	22
15	23		1. That 54.1-3442.02 of the Code of Virginia is amended and reenacted and that the Code of Virginia is amended by adding in Title 32.1 a chapter numbered 7.3, consisting of sections numbered 32.1-276.12 through 32.1-276.19, as follows:
16	24
17	25		CHAPTER 7.3.
18	26
19	27		PRESCRIPTION DRUG AFFORDABILITY BOARD.
20	28
21	29		32.1-276.12. Definitions.
22	30
23	31		As used in this chapter, unless the context requires a different meaning:
24	32
25	33		"Biologic" means a drug that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. 262.
26	34
27	35		"Biosimilar" means a drug that is produced or distributed in accordance with a biologics license application approved under 42 U.S.C. 262(k)(3).
28	36
29	37		"Board" means the Prescription Drug Affordability Board.
30	38
31	39		"Brand-name drug" means a drug that is produced or distributed in accordance with an original new drug application approved under 21 U.S.C. 355(c). "Brand-name drug" does not include an authorized generic drug as defined by 42 C.F.R. 447.502.
32	40
33	41		"Generic drug" means (i) a retail drug that is marketed or distributed in accordance with an abbreviated new drug application approved under 21 U.S.C. 355(j), (ii) an authorized generic drug as defined by 42 C.F.R. 447.502, or (iii) a drug that entered the market before 1962 that was not originally marketed under a new drug application.
34	42
35	43		"Manufacturer" means an entity that (i) (a) owns the patent to a prescription drug product, (b) engages in the manufacture of a prescription drug product, (c) enters into a lease with another manufacturer to market and distribute a prescription drug product under the entity's own name, or (d) is the labeled entity of the generic product at the point of manufacture and (ii) sets or changes the wholesale acquisition cost of the prescription drug product it manufactures or markets.
36	44
37	45		"Nonprofit data services organization" has the same meaning as set forth in 32.1-23.4.
38	46
39	47		"Pharmacy benefits manager" has the same meaning as provided in 38.2-3465.
40	48
41	49		"Prescription drug product" means a drug or biological product receiving approval under a drug application pursuant to 21 U.S.C. 355(b) or under a biologics license application approved under 42 U.S.C. 262.
42	50
43	51		"Stakeholder council" means the Prescription Drug Affordability Board stakeholder council.
44	52
45	53		32.1-276.13. Prescription Drug Affordability Board established.
46	54
47	55		A. There is hereby established in the Department of Health the Prescription Drug Affordability Board for the purpose of protecting citizens of the Commonwealth and other stakeholders within the health care system from the high costs of prescription drug products.
48	56
49	57		B. The Board shall be composed of five nonlegislative citizen members that shall be appointed as follows: two members to be appointed by the Speaker of the House of Delegates, two members to be appointed by the Senate Committee on Rules, and one member to be appointed by the Governor who shall be a representative of a local government in the Commonwealth. The Governor shall appoint three alternate nonlegislative citizen members of the Board. Members of the Board shall have expertise in health care, health care economics, the federal 340B Drug Pricing Program and its impacts on Virginia's federally qualified health centers, or clinical medicine. A member or alternate member of the Board shall not be an employee of, a board member of, or a consultant to a manufacturer or trade association for manufacturers. Any conflict of interest, including whether an individual has an association, including a financial or personal association, that has the potential to bias or has the appearance of biasing the individual's decisions in matters related to the Board or the conduct of the Board's activities shall be disclosed and considered when appointing members and alternate members to the Board.
50	58
51	59		C. After the initial staggering of terms, members and alternate members shall be appointed for a term of five years. Vacancies occurring other than by expiration of a term shall be filled for the unexpired term. Vacancies shall be filled in the same manner as the original appointments.
52	60
53	61		D. The Board shall elect a chairman and vice-chairman from among its membership. A majority of the members shall constitute a quorum. The meetings of the Board shall be held at the call of the chairman or whenever the majority of the members so request.
54	62
55	63		E. The Board shall hire an executive director, general counsel, and staff to support the Board's activities. Staff of the Board shall receive a salary as provided in the budget of the Board and in accordance with the general appropriation act. A member of the Board may receive compensation as a member of the Board in accordance with the general appropriation act and is entitled to reimbursement for expenses authorized by travel regulations promulgated pursuant to 2.2-2823.
56	64
57	65		F. Subject to subdivision 2, the Board shall meet in open session at least four times annually to review prescription drug product information. The following provisions shall also apply to meetings of the Board:
58	66
59	67		1. The Chair may cancel or postpone a meeting if there is no business to transact.
60	68
61	69		2. The following actions by the Board shall be made in open session: (i) any deliberations on whether to subject a prescription drug product to an affordability review under 32.1-276.16; (ii) any vote on whether to impose an upper payment limit amount on purchases, payments, and payer reimbursements of prescription drug products in the Commonwealth; and (iii) any significant decision by the Board.
62	70
63	71		3. The Board may meet in closed session to discuss proprietary data and information.
64	72
65	73		4. The Board shall provide public notice of each Board meeting at least three weeks in advance of the meeting.
66	74
67	75		5. Materials for each Board meeting shall be made available to the public at least two weeks in advance of the meeting.
68	76
69	77		6. The Board shall provide an opportunity for public comment at each open meeting of the Board.
70	78
71	79		7. The Board shall provide the public with the opportunity to provide written comments on pending decisions of the Board.
72	80
73	81		8. The Board may allow expert testimony at its meetings, including when the Board meets in closed session.
74	82
75	83		G. Any member of the Board shall recuse himself from decisions related to prescription drug products if the member, or an immediate family member of the member, has received or could receive either of the following:
76	84
77	85		1. A direct financial benefit of any amount deriving from the result or finding of a study or determination by or for the Board; or
78	86
79	87		2. A financial benefit from any person that owns, manufactures, or provides prescription drug products, services, or items to be studied by the Board that in the aggregate exceeds $5,000 per year.
80	88
81	89		For the purposes of subdivision 1, a direct financial benefit includes honoraria, fees, stock, the value of the member's or immediate family member's stock holdings, and any direct financial benefit deriving from the finding of a review conducted pursuant to this chapter.
82	90
83	91		A conflict of interest shall be disclosed (i) by the Board when hiring Board staff, (ii) by the appointing authority when appointing members and alternate members to the Board and members to the stakeholder council, and (iii) by the Board when a member of the Board is recused in any final decision resulting from a review of a prescription drug product. A conflict of interest shall be disclosed in advance of the first open meeting after the conflict is identified or within five days after the conflict is identified, whichever is sooner.
84	92
85	93		A conflict of interest disclosed pursuant to this subsection shall be posted on the website of the Board unless the Chair of the Board recuses the member from any final decision resulting from a review of a prescription drug product. Such posting shall include the type, nature, and magnitude of the interests of the member involved.
86	94
87	95		H. Members and alternate members of the Board, Board staff, and third-party contractors shall not accept any gift or donation of services or property that indicates a potential conflict of interest or has the appearance of biasing the work of the Board.
88	96
89	97		32.1-276.14. Powers and duties of the Board.
90	98
91	99		A. The Board shall assess pricing information for prescription drug products by accessing available pricing information based on state reporting and transparency requirements, including prescription drug product price transparency information collected and compiled by a nonprofit data services organization and the Department of Health pursuant to 32.1-23.4, and assessing spending for prescription drug products in the Commonwealth.
92	100
93	101		B. The Board may enter into a contract with a qualified, independent third party for any service necessary to carry out the powers and duties of the Board. Unless permission is granted by the Board, a third party hired by the Board shall not release, publish, or otherwise use any information to which the third party has access under its contract with the Board.
94	102
95	103		C. In addition to the powers set forth in this chapter, the Board may promulgate regulations for the implementation of this chapter.
96	104
97	105		32.1-276.15. Stakeholder council.
98	106
99	107		A. The Board shall create a stakeholder council for the purpose of providing stakeholder input to assist the Board in making decisions as required under this chapter. The stakeholder council shall consist of 11 nonlegislative citizen members appointed in accordance with this section. Members shall include manufacturers of brand-name drugs and generic drugs, providers that dispense or administer prescription drug products, suppliers of prescription drug products, and consumers of prescription drug products. No more than one stakeholder council member shall be appointed to represent any single organization or entity.
100	108
101	109		B. The members of the stakeholder council shall be appointed as follows: five members to be appointed by the Speaker of the House of Delegates, one of whom shall be a representative of a rare disease and patient advocacy organization; three members to be appointed by the Senate Committee on Rules; and three members to be appointed by the Governor.
102	110
103	111		C. The members of the stakeholder council shall have knowledge in one or more of the following subjects: (i) the pharmaceutical business model, (ii) supply chain business models, (iii) the practice of medicine or clinical training, (iv) consumer or patient perspectives, (v) health care costs trends and drivers, (vi) clinical and health services research, or (vii) the health care marketplace in the Commonwealth.
104	112
105	113		D. After the initial staggering of terms, members shall be appointed for a term of three years. Vacancies occurring other than by expiration of a term shall be filled for the unexpired term. Vacancies shall be filled in the same manner as the original appointments.
106	114
107	115		E. The Chair of the Board shall select one member of the stakeholder council to serve as chair of the stakeholder council.
108	116
109	117		F. No member of the stakeholder council shall receive compensation as a member of the stakeholder council, but members shall be entitled to reimbursement for expenses under standard state travel regulations promulgated pursuant to 2.2-2823.
110	118
111	119		32.1-276.16. Drug cost affordability review.
112	120
113	121		A. Nothing in this section shall be construed to prevent a manufacturer from marketing a prescription drug product approved by the U.S. Food and Drug Administration (FDA) while the product is under review by the Board.
114	122
115	123		B. The Board shall identify the following prescription drug products offered for sale in the Commonwealth:
116	124
117	125		1. Brand-name drugs or biologics that, as adjusted annually for inflation in accordance with the Consumer Price Index, have (i) a wholesale acquisition cost of $60,000 or more per year or course of treatment or (ii) a wholesale acquisition cost increase of $3,000 or more in any 12-month period;
118	126
119	127		2. Biosimilars that have a wholesale acquisition cost that is not at least 20 percent lower than the referenced brand biologic at the time the biosimilars are launched and that have been suggested for review by members of the public, medical professionals, or other stakeholders;
120	128
121	129		3. a. Generic drugs that, as adjusted for inflation in accordance with the Consumer Price Index, have a wholesale acquisition cost of $100 or more for (i) a 30-day supply lasting a patient for a period of 30 consecutive days based on the recommended dosage approved for labeling by the FDA, (ii) a supply lasting a patient fewer than 30 days based on the recommended dosage approved for labeling by the FDA, or (iii) one unit of the drug if the labeling approved by the FDA does not recommend any finite dosage;
122	130
123	131		b. Generic drugs that, as adjusted for inflation in accordance with the Consumer Price Index, have a wholesale acquisition cost of at least $100 for a 30-day supply or a course of treatment of less than 30 days and that increased by 200 percent or more during the immediately preceding 12-month period, as determined by the difference between the resulting wholesale acquisition cost and the average of the wholesale acquisition cost reported over the immediately preceding 12 months; and
124	132
125	133		4. Other prescription drug products that may create affordability challenges for the health care system in the Commonwealth and high out-of-pocket costs for patients, including drugs used to address public health emergencies.
126	134
127	135		The Board shall not be required to identify every prescription drug product that meets the criteria of this subsection.
128	136
129	137		C. After identifying prescription drug products as required by subsection B, soliciting public input on prescription drug products thought to be creating affordability challenges, and compiling preliminary information about the cost of the product, patient cost sharing for the product, health plan spending on the product, stakeholder input, and other information as determined by the Board, the Board shall determine whether to conduct an affordability review for each identified prescription drug product. Relevant information for conducting an affordability review may include any document or research related to the manufacturer's selection of the introductory price or price increase of the prescription drug product, including life-cycle management, net average prices in the Commonwealth, market competition and context, projected revenue, patient assistance programs specific to a prescription drug product, estimated or actual manufacturer price concessions in the market, the estimated value or cost effectiveness of the prescription drug product, and other information as determined by the Board. Failure of a manufacturer to provide the Board with relevant information for an affordability review shall not affect the Board's authority to conduct such a review.
130	138
131	139		D. An affordability review conducted by the Board shall determine whether the prescription drug product that is fully consistent with the labeling approved by the FDA or standard medical practice has led or will lead to affordability challenges for the health care system in the Commonwealth or high out-of-pocket costs for patients. To the extent practicable, in determining whether a prescription drug product has led or will lead to an affordability challenge, the Board shall consider the following factors:
132	140
133	141		1. The wholesale acquisition cost for the prescription drug product sold in the Commonwealth;
134	142
135	143		2. The average monetary price concession, discount, or rebate the manufacturer provides or is expected to provide to health plans in the Commonwealth as reported by manufacturers and health plans, expressed as a percentage of the wholesale acquisition cost for the prescription drug product under review;
136	144
137	145		3. The total amount of the price concession, discount, or rebate the manufacturer provides to each pharmacy benefits manager operating in the Commonwealth for the prescription drug product under review, as reported by manufacturers and pharmacy benefits managers, expressed as a percentage of wholesale acquisition cost;
138	146
139	147		4. The price at which therapeutic alternatives have been sold in the Commonwealth;
140	148
141	149		5. The average monetary concession, discount, or rebate the manufacturer provides or is expected to provide to health plan payers and pharmacy benefits managers in the Commonwealth for therapeutic alternatives;
142	150
143	151		6. The cost to health plans based on patient access consistent with FDA-labeled indications and recognized standard medical practice;
144	152
145	153		7. The impact on patient access resulting from the cost of the prescription drug product relative to insurance benefit design;
146	154
147	155		8. The current or expected dollar value of drug-specific patient access programs that are supported by the manufacturer;
148	156
149	157		9. The relative financial impacts to health, medical, or social services costs as can be quantified and compared to baseline effects of existing therapeutic alternatives;
150	158
151	159		10. The average patient copay or other cost sharing for the prescription drug product in the Commonwealth;
152	160
153	161		11. Any information a manufacturer chooses to provide; and
154	162
155	163		12. Any other factors as determined by the Board through regulations adopted by the Board.
156	164
157	165		E. If the Board finds that the spending on a prescription drug product reviewed under this section has led or will lead to an affordability challenge for the health care system in the Commonwealth or high out-of-pocket costs for citizens of the Commonwealth, particularly patients experiencing physical and mental illnesses, communities affected by the opioid crisis, state and local governments, commercial health plans, health care providers, pharmacies licensed in the Commonwealth, and other stakeholders within the health care system, the Board shall establish an upper payment limit amount after considering exceptional costs of administering the prescription drug product, the cost of delivering the prescription drug product to customers, and other relevant administrative costs related to the prescription drug product. In determining whether a prescription drug product creates an affordability challenge or in determining an upper payment limit amount, the Board shall not utilize a cost-effectiveness analysis that includes the cost-per-quality adjusted life year or similar measure to identify subpopulations for which a treatment would be less cost-effective due to severity of illness, age, or preexisting disability. For any treatment that extends life, if the Board uses a cost-effectiveness analysis, such analysis shall weigh the value of all additional lifetime gained equally for all patients regardless of severity of illness, age, or preexisting disability. If the Board establishes an upper payment limit amount pursuant to this subsection, the Board shall examine how the upper payment limit amount will affect entities operating pursuant to 340B of the federal Public Health Service Act, 42 U.S.C. 256b.
158	166
159	167		F. An upper payment limit amount established by the Board pursuant to subsection E shall apply to all purchases and payer reimbursements of the prescription drug product intended for use by individuals in the Commonwealth in person, by mail, or by any other means. Such upper payment limit amount shall become effective no sooner than six months after it is announced by the Board. Such upper payment limit amount shall be exclusive of applicable pharmacy dispensing fees and provider administration fees. State-licensed independent pharmacies shall not be reimbursed less than an upper payment limit amount.
160	168
161	169		G. The Board may adopt the Medicare maximum fair price in 1191(c) of Title XVII of the Social Security Act, 42 U.S.C. 1395 et seq., for a prescription drug product as the upper payment limit amount established pursuant to subsection E. The Board shall not establish an upper payment limit amount different than the Medicare maximum fair price for any prescription drug product included in 1191(c) of Title XVII of the Social Security Act, 42 U.S.C. 1395 et seq.
162	170
163	171		H. State regulated health plans shall inform the Board of how the cost savings related to an upper payment limit amount are directed to the benefit of enrollees with a priority on enrollee cost sharing.
164	172
165	173		I. Any information submitted to the Board in accordance with this section shall be subject to public inspection only to the extent required under the Virginia Freedom of Information Act ( 2.2-3700 et seq.).
166	174
167	175		32.1-276.17. Remedies; appeals.
168	176
169	177		A. The Office of the Attorney General may pursue any appropriate available remedy under state law in enforcing the provisions of this chapter.
170	178
171	179		B. Any person aggrieved by a decision of the Board may request an appeal of the decision within 30 days after the decision is made. The Board shall hear the appeal and make a final decision within 60 days after the appeal is requested.
172	180
173	181		C. Any person aggrieved by a final decision of the Board may petition for judicial review as provided by the Administrative Process Act ( 2.2-4000 et seq.).
174	182
175	183		32.1-276.18. Reporting requirements.
176	184
177	185		A. On or before December 31, 2026, and annually thereafter, the Board shall submit to the Chair of the Senate Committee on Education and Health, the Chair of the Senate Committee on Commerce and Labor, the Chair of the House Committee on Health and Human Services, and the Chair of the House Committee on Labor and Commerce a report that includes the following:
178	186
179	187		1. Price trends for prescription drug products in the Commonwealth and nationwide;
180	188
181	189		2. Prescription drug products that were subject to Board review during the previous 12-month period, including the number of prescription drug products subject to review, the results of the reviews, and the number and disposition of appeals and judicial reviews of Board decisions; and
182	190
183	191		3. Any recommendations the Board may have regarding further legislation needed to improve prescription drug affordability in the Commonwealth.
184	192
185	193		B. On or before July 1, 2026, the Board shall study the operations of the generic drug market in the United States, including a review of physician-administered drugs. The study shall consider (i) the prices of generic drugs on a year-over-year basis, (ii) the degree to which generic drug prices affect yearly insurance premium changes, (iii) annual changes in insurance cost sharing for generic drugs, (iv) the potential for and history of generic drug shortages, (v) the degree to which generic drug prices affect yearly Medicaid spending in the Commonwealth, and (vi) any other relevant study questions. The Board shall report this study to the Chairs of the Senate and House committees listed in subsection A.
186	194
187	195		32.1-276.19. Relation to other health benefit plans.
188	196
189	197		The provisions of this chapter obligate state-sponsored and state-regulated health plans and health programs to limit drug reimbursements and drug payment amounts to no more than the Board-established upper payment limit amount. Plans providing health care benefits pursuant to Part D of Title XVIII of the Social Security Act, 42 U.S.C. 1395 et seq., known as Medicare Part D, shall not be bound by decisions of the Board, and any such plans may choose to reimburse more than the Board-established upper payment limit amount. Providers who dispense and administer prescription drug products to citizens of the Commonwealth shall be bound to bill all health plan payers no more than the Board-established upper payment limit amount without regard to whether or not a Medicare Part D plan chooses to reimburse the provider above the upper payment limit amount.
190	198
191	199		54.1-3442.02. Prescription drug price transparency.
192	200
193	201		A. As used in this section:
194	202
195	203		"Biosimilar" means a drug that is produced or distributed pursuant to a biologics license application approved under 42 U.S.C. 262(k)(3).
196	204
197	205		"Brand-name drug" means a prescription drug approved under 21 U.S.C. 355(b) or 42 U.S.C. 262.
198	206
199	207		"Generic drug" means a prescription drug approved under 21 U.S.C. 355(j) or 42 U.S.C. 262(k).
200	208
201	209		"Biosimilar," "brand-name drug," and "generic drug" have the same meanings as provided in 32.1-276.12.
202	210
203	211		"New prescription drug" means a drug or biological product receiving initial approval under an original new drug application pursuant to 21 U.S.C. 355(b) or under a biologics license application under 42 U.S.C. 262.
204	212
205	213		"Nonprofit data services organization" has the same meaning as set forth in 32.1-23.4.
206	214
207	215		"Pharmacy benefits manager" has the same meaning as set forth in 38.2-3407.15:4.
208	216
209	217		"Wholesale acquisition cost" has the same meaning as set forth in 42 U.S.C. 1395w-3a(c)(6)(B).
210	218
211	219		B. Every manufacturer shall report annually by April 1 to the nonprofit organization with which the Department of Health has entered into a contract or agreement pursuant to 32.1-23.4, for each (i) brand-name drug and biologic other than a biosimilar with a wholesale acquisition cost of $100 or more for a 30-day supply or a single course of treatment and any increase of 15 percent or more in the wholesale acquisition cost of such brand-name drug or biologic over the preceding calendar year; (ii) biosimilar with an initial wholesale acquisition cost that is not at least 15 percent less than the wholesale acquisition cost of the referenced brand biologic at the time the biosimilar is launched; and (iii) generic drug with a price increase that results in an increase in the wholesale acquisition cost of such generic drug that is equal to 200 percent or more during the preceding 12-month period, when the wholesale acquisition cost of such generic drug is equal to or greater than $100, annually adjusted by the Consumer Price Index for All Urban Consumers, for a 30-day supply, with such increase defined as the difference between the wholesale acquisition cost of the generic drug after such increase and the average wholesale acquisition cost of such generic drug during the previous 12 months, the following information:
212	220
213	221		1. The name of the prescription drug;
214	222
215	223		2. Whether the drug is a brand name or generic;
216	224
217	225		3. The effective date of the change in wholesale acquisition cost;
218	226
219	227		4. Aggregate, company-level research and development costs for the most recent year for which final audit data is available;
220	228
221	229		5. The name of each of the manufacturer's new prescription drugs approved by the U.S. Food and Drug Administration within the previous three calendar years;
222	230
223	231		6. The name of each of the manufacturer's prescription drugs that, within the previous three calendar years, became subject to generic competition and for which there is a therapeutically equivalent generic version; and
224	232
225	233		7. A concise statement regarding the factor or factors that caused the increase in wholesale acquisition cost.
226	234
227	235		C. A manufacturer's obligations pursuant to this section shall be fully satisfied by the submission to the nonprofit data services organization with which the Department of Health has entered into a contract pursuant to 32.1-23.4 of information and data that a manufacturer includes in the manufacturer's annual consolidation report on Securities and Exchange Commission Form 10-K or any other public disclosure.
228	236
229	237		D. The nonprofit organization with which the Department of Health has entered into a contract or agreement pursuant to 32.1-23.4 shall provide the Prescription Drug Affordability Board established pursuant to 32.1-276.13 access to the data collected pursuant to subsection B.
230	238
231	239		2. That the members of the Prescription Drug Affordability Board established by 32.1-276.13 of the Code of Virginia, as created by this act, shall be appointed by July 1, 2026, and that the Prescription Drug Affordability Board may begin its work regardless of any delay in appointing members to the stakeholder council established by 32.1-276.15 of the Code of Virginia, as created by this act.
232	240
233	241		3. That the Prescription Drug Affordability Board established by 32.1-276.13 of the Code of Virginia, as created by this act, shall establish pursuant to subsection E of 32.1-276.16 of the Code of Virginia, as created by this act, no more than 12 upper payment limit amounts annually between July 1, 2026, and January 1, 2029.
234	242
235	243		4. That the initial appointments of nonlegislative citizen members and alternative members of the Prescription Drug Affordability Board (the Board) established by 32.1-276.13 of the Code of Virginia, as created by this act, shall be staggered as follows: one member for a term of three years and one member for a term of five years, appointed by the Speaker of the House of Delegates; one member for a term of two years and one member for a term of four years, appointed by the Senate Committee on Rules; and one member for a term of one year, one alternative member for a term of three years, one alternative member for a term of four years, and one alternative member for a term of five years, appointed by the Governor.
236	244
237	245		5. That the initial appointments of nonlegislative citizen members to the stakeholder council established by 32.1-276.15 of the Code of Virginia, as created by this act, shall be staggered as follows: one member for a term of one year, two members for a term of two years, and two members for a term of three years, appointed by the Speaker of the House of Delegates; one member for a term of one year, one member for a term of two years, and one member for a term of three years, appointed by the Senate Committee on Rules; and one member for a term of one year, one member for a term of two years, and one member for a term of three years, appointed by the Governor.
238	246
239	247		6. That the provisions of the first enactment of this act shall become effective on July 1, 2026.